The European Investment Bank (EIB) is lending up to €100 million to Swedish medical-technology company Elekta AB to advance treatments for a range of cancers and neurological diseases, according to a press release by the EIB. The financing will support Elekta’s research and development in radiotherapy, radiosurgery, brachytherapy, and the software used to plan and deliver therapies. Most of the work will take place in Sweden and the Netherlands between 2026 and 2029. The loan aims to boost treatments for millions of patients suffering from conditions ranging from tumors to essential tremor and certain forms of epilepsy. It also strengthens Europe’s position in strategic medical technologies.
Stockholm-based Elekta develops technologies to treat illnesses including brain tumors, breast cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer, and essential tremor. The company’s radiotherapy treatments serve more than 2 million patients worldwide each year. Elekta sells its products in more than 120 countries and operates in roughly 40 nations. It employs about 4,000 people and is listed on Nasdaq Stockholm. The company plans to invest around €200 million in its research program between 2026 and 2029.
The EIB loan will cover up to half of these planned investments. Elekta’s research program includes new radiotherapy, radiosurgery, and brachytherapy systems, as well as software for treatment planning, workflow automation, and precision delivery. The goal is to improve the accuracy and efficiency of treatments. It also seeks to help healthcare providers treat more patients as demand for cancer care grows. The financing aligns with wider efforts to bring advanced radiotherapy into routine clinical practice.
“Europe has world-leading medical-technology companies and we need to make sure they can continue investing and innovating here,” said EIB Vice-President Karl Nehammer.
He added that the financing will support the next generation of cancer and neurological treatments. Elekta Chief Financial Officer Klara Eiritz noted that healthcare providers are seeking solutions that help them treat more patients while maintaining quality and precision. “This financing provides additional flexibility to support our long-term strategy and continued investments in innovation that improve clinical outcomes, operational efficiency and the patient experience,” she said. The remarks underline the shared ambition of both institutions.
The loan supports the EIB Group’s TechEU program to strengthen European investment in strategic technologies and innovation. It also contributes to European Union goals for health research, competitiveness, and advanced medical technologies. Research activities will be concentrated in Sweden and the Netherlands during the 2026–2029 period. The initiative reinforces Europe’s capacity to deliver precision radiation medicine at scale. It marks a further step in expanding access to advanced cancer and neurological care.